College of Medicine, Institute of Life Science, Swansea University, Swansea SA2 8PP, UK.
Thorax. 2012 Jul;67(7):660-2. doi: 10.1136/thoraxjnl-2012-201825. Epub 2012 May 5.
Clinical experience and now genetic data indicate that asthma is a heterogeneous clinical syndrome--clinical cases emerge, proceed and respond to treatments in different ways. Currently the diagnosis of asthma (as enunciated in national guidelines) is based on incisive clinical methods, supported by lung function testing that substantiates labile or reversible bronchial airflow obstruction. But this approach alone is insufficient to address the diagnostic and therapeutic challenges presented by asthma's heterogeneity. This article contends that bronchial pathology (with molecular and morphologic analysis) should be adopted into the mainstream clinical practice of asthma so as to clarify the nature of the bronchial disorder in compliant patients not settling securely on moderate-dose inhaled corticosteroid. This would allow a differentiated approach to appropriate therapeutics--those already available and those yet to be developed.
临床经验和现有遗传数据表明,哮喘是一种异质性临床综合征——临床病例以不同的方式出现、进展和对治疗作出反应。目前,哮喘的诊断(如国家指南所述)基于敏锐的临床方法,并辅以证实不稳定或可逆性支气管气流阻塞的肺功能测试。但是,仅采用这种方法不足以应对哮喘异质性带来的诊断和治疗挑战。本文认为,支气管病理学(采用分子和形态分析)应纳入哮喘的主流临床实践中,以明确对中剂量吸入皮质类固醇治疗反应不佳的患者的支气管病变性质。这将为现有和即将开发的治疗方法提供差异化的治疗选择。